- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07524335
Aspirin i subklinisk koronararteriesygdom: Et pilotstudie med randomiseret kontrol (ASCAD-P)
Aspirin ved subklinisk koronararteriesygdom: Et pilot randomiseret kontrolleret forsøg
In patients with subclinical coronary artery disease, the ASCAD-P study aims to assess the feasibility of a larger phase 3 pragmatic randomized controlled trial comparing prescription versus no prescription of low-dose aspirin in routine clinical practice.
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
Cardiovascular disease remains the leading cause of mortality worldwide. Recent large randomized trials have demonstrated limited net clinical benefit of aspirin in unselected primary prevention populations, leading to guideline recommendations against its systematic routine use for cardiovascular protection.
Patients with subclinical coronary artery disease represent a high-risk subgroup. These individuals have documented coronary artery disease but have not experienced overt cardiovascular events or undergone revascularization. Observational data suggest that this population carries a substantially increased risk of myocardial infarction compared with individuals without coronary atherosclerosis. However, the benefit-risk balance of aspirin in this intermediate-risk group remains uncertain
Primary Objective:
To evaluate the recruitment rate of a pilot randomized trial comparing low-dose aspirin prescription versus no prescription.
Secondary Objectives
To evaluate key feasibility metrics, including:
- The proportion of eligible patients who are randomized;
- Adherence and persistence to the assigned intervention at 12 months;
- The proportion of patients who do not complete the 12-month follow-up;
- Barriers to recruitment, adherence, and retention.
Exploratory Objectives:
To explore clinical outcomes at 12 months, including:
- The incidence of clinically significant bleeding events (BARC type 2, 3, or 5) and bleeding site;
- The incidence of major adverse cardiovascular events (MACE), defined as a composite of all-cause mortality, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularization;
- Individual components of the composite endpoint;
- Cardiovascular mortality;
- Adverse Events and Serious Adverse Events.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
- Navn: Cyril Gagnon, MD
- Telefonnummer: 2698 514-376-3330
- E-mail: cyril.gagnon@umontreal.ca
Undersøgelse Kontakt Backup
- Navn: Samara Bloom, MSc
- Telefonnummer: 2698 514-376-3330
- E-mail: samara.bloom@icm-mhi.org
Studiesteder
-
-
Quebec
-
Montreal, Quebec, Canada, H1T 1C8
- Rekruttering
- Montreal Heart Institute
-
Ledende efterforsker:
- Guillaume Marquis-Gravel, MD, MSc
-
Kontakt:
- Cyril Gagnon, MD
- Telefonnummer: 2698 514-376-3330
- E-mail: cyril.gagnon@umontreal.ca
-
Kontakt:
- Samara Bloom, MSc
- Telefonnummer: 2698 514-376-3330
- E-mail: samara.bloom@icm-mhi.org
-
Ledende efterforsker:
- Pierre Elias, MD
-
Ledende efterforsker:
- Cyril Gagnon, MD
-
Ledende efterforsker:
- Alino Demean Loghin, MD
-
Québec, Quebec, Canada, G1V 4G5
- Ikke rekrutterer endnu
- Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ)
-
Ledende efterforsker:
- Tomas Cieza, MD
-
Ledende efterforsker:
- Roubie Dib, MD
-
Kontakt:
- Roubie Dib, MD
- Telefonnummer: (418) 656-8711
- E-mail: roubie.dib.1@ulaval.ca
-
Kontakt:
- Sara Desjardins, MD
- Telefonnummer: (418) 656-8711
- E-mail: sara.desjardins.2@ulaval.ca
-
Ledende efterforsker:
- Sara Desjardins, MD
-
Trois-Rivières, Quebec, Canada, G8Z 3R9
- Ikke rekrutterer endnu
- Centre hospitalier affilié universitaire régional (CHAUR)
-
Ledende efterforsker:
- Vincent Spagnoli, MD
-
Kontakt:
- Farzin Brian Haghighat
- Telefonnummer: (819) 697-3333
- E-mail: farzin.brian.haghighat@umontreal.ca
-
Ledende efterforsker:
- Farzin Brian Haghighat
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Documented coronary atherosclerosis, as defined by one of the following criteria:
- Coronary artery calcium (CAC) score > 0;
- Cardiac CT angiography (CCTA) / CoroScan: lesions <70% in the right coronary (RCA), left anterior descending (LAD), and circumflex (Cx) arteries or their branches, and <50% in the left main coronary artery;
- Coronary angiography: lesions <70% in the right coronary (RCA), left anterior descending (LAD), and circumflex (Cx) arteries or their branches, and <50% in the left main coronary artery; if performed, physiological coronary assessments (FFR, dPR, iFR, etc.) and intracoronary imaging (IVUS or OCT) must be negative for significant disease.
-
Willing and able to provide informed consent and comply with study procedures
Exclusion Criteria:
- History of myocardial infarction (MI), coronary revascularization, stroke, transient ischemic attack (TIA), or peripheral arterial revascularization procedure;
- Current prescription or clear indication for aspirin, low-molecular-weight heparin (LMWH), direct oral anticoagulants, or any other antithrombotic medication;
- Clear contraindication to aspirin;
- History of significant bleeding within the past year;
- Severe illness with limited life expectancy (i.e., <5 years);
- Any condition that, in the investigator's judgment, would make participation unsafe for the patient.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Low-dose Aspirin Prescription
Aspirin 81 mg orally once daily prescription |
Aspirin 81 mg orally once daily |
|
Andet: No Prescription
No prescription of aspirin 81 mg orally once daily |
No prescription of aspirin 81 mg orally once daily |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Monthly Recruitment Rate
Tidsramme: 12 months following study enrollment initiation
|
Average monthly patient recruitment rate: 0 ≤ Mean rate (patients/month) < 2 = study not feasible; 2 ≤ Mean rate (patients/month) < 4 = study feasible with protocol modifications; ≥ 4 Mean rate (patients/month) = study feasible without major protocol modifications. |
12 months following study enrollment initiation
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Barrierer for rekruttering, overholdelse og patienttilbageholdelse
Tidsramme: Fra rekruttering til opfølgningens afslutning (12 måneder)
|
Fra rekruttering til opfølgningens afslutning (12 måneder)
|
|
|
Proportion of Eligible Patients Randomized
Tidsramme: 12 months following study enrollment initiation
|
Proportion of eligible patients who are randomized: 0% ≤ Proportion < 30% = study not feasible, major protocol modifications required; 30% ≤ Proportion < 61% = study feasible with protocol modifications; ≥ 61% = study feasible without protocol modifications. |
12 months following study enrollment initiation
|
|
Intervention Adherence
Tidsramme: From randomization to the end of follow-up (12 months)
|
Proportion of days on which patients take the assigned intervention (adherence): 0% ≤ Mean proportion < 25% = study not feasible, major protocol modifications required; 25% ≤ Mean proportion < 74% = study feasible with protocol modifications; ≥ 74% = study feasible without protocol modifications. |
From randomization to the end of follow-up (12 months)
|
|
Intervention Persistence
Tidsramme: From randomization to end of follow-up (12 months)
|
Proportion of patients who still take the assigned intervention at 12 months of follow-up (persistence): 0% ≤ Proportion < 25% = study not feasible, major protocol modifications required; 25% ≤ Proportion < 70% = study feasible with protocol modifications; ≥ 70% = study feasible without protocol modifications. |
From randomization to end of follow-up (12 months)
|
|
Proportion of Patients Lost to Follow-up
Tidsramme: End of follow-up (12 months)
|
Proportion of patients who do not complete the 12-month follow-up visit: ≥ 10% = study not feasible, major protocol modifications required; 6% ≤ Proportion < 10% = study feasible with protocol modifications; 0% ≤ Proportion < 6% = study feasible without protocol modifications. |
End of follow-up (12 months)
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Blødningsrate (BARC 2, 3, 5)
Tidsramme: Fra tilmelding til opfølgningens afslutning (12 måneder)
|
Fra tilmelding til opfølgningens afslutning (12 måneder)
|
|
|
Bivirkningsrate (AE) og alvorlig bivirkningsrate (SAE)
Tidsramme: Fra tilmelding til opfølgningens afslutning (12 måneder)
|
Fra tilmelding til opfølgningens afslutning (12 måneder)
|
|
|
Major Adverse Cardiovascular Event (MACE) Rate
Tidsramme: From enrollment to the end of follow-up (12 months)
|
MACE rate (all-cause mortality, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularization) at 12 months of follow-up |
From enrollment to the end of follow-up (12 months)
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2026-3694
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .